Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models (Q34615883)

3 August 2017

1 reference

title

Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models (English)

1 reference

3 August 2017

Alasdair MacGowan

1

1 reference

3 August 2017

Karen Bowker

series ordinal

2

1 reference

3 August 2017

publication date

1 April 2002

1 reference

International Journal of Antimicrobial Agents

3 August 2017

published in

1 reference

3 August 2017

volume

19

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

291-298

1 reference

Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900027-4

7 January 2021

10.1016/S0924-8579(02)00027-4

Identifiers

DOI

1 reference

3 August 2017

1 reference